Coya Therapeutics is a clinical-stage biotechnology company developing therapies to enhance regulatory T cell function. Its pipeline includes Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy, with programs such as COYA 302 in ALS and other neurodegenerative indications.
Coya Therapeutics detailed plans for a Phase 2 trial of combination immunotherapy targeting neuroinflammation in ALS, following a four-patient study showing biomarker improvements and reported slowing of disease progression.
Dr. Reddy's Laboratories secures FDA acceptance for DRL-AB, the first abatacept biosimilar application in the U.S., targeting a market worth $3.7 billion annually and positioning the company for first-mover advantage.
Engineered regulatory T cell therapies are progressing through clinical trials for autoimmune diseases and organ transplant rejection, with CAR-Treg candidates showing promising early results in rheumatoid arthritis and other conditions.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07161999 |
Study of COYA 302 for the Treatment of ALS |
RECRUITING | PHASE2 |
